© Reuters. FILE PHOTO: A sign stands outside a Bristol Myers Squibb facility in Cambridge, Massachusetts, U.S., May 20, 2021. REUTERS/Brian Snyder/File Photo
(Reuters) – Bristol Myers (NYSE:) Squibb Co has expressed interest in buying autoimmune disease drug developer Aurinia Pharmaceuticals (NASDAQ:) Inc, Bloomberg News reported on Friday, citing people familiar with the matter.
Aurinia’s shares closed up nearly 27% on the news, giving it a market capitalization of $3.59 billion, according to Refinitiv data.
The report said no final decision has been made and that Bristol Myers could opt out of a potential deal.
Both Bristol Myers and Aurinia declined to comment on the matter.
Aurinia sells a treatment for a kidney disorder called lupus nephritis and is testing out treatments for other autoimmune and kidney diseases, according to its website.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Be the first to comment